(EOLS) Evolus - Overview

Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic | Exchange NASDAQ (USA) | Currency USD | Market Cap: 284m | Total Return -67.3% in 12m

Stock Injectables, Cosmetics, Aesthetics
Total Rating 21
Risk 36
Buy Signal -1.80
Drug Manufacturers - Specialty & Generic -2.2
Pharmaceuticals -4.7
Market Cap: 284m
Avg Trading Vol: 4.77M USD
ATR: 7.51%
Peers RS (IBD): 1.9
Risk 5d forecast
Volatility60.9%
Rel. Tail Risk-14.2%
Reward TTM
Sharpe Ratio-1.28
Alpha-78.73
Character TTM
Beta0.787
Beta Downside0.635
Drawdowns 3y
Max DD77.47%
CAGR/Max DD-0.29
EPS (Earnings per Share) EPS (Earnings per Share) of EOLS over the last years for every Quarter: "2021-03": -0.2, "2021-06": -0.19, "2021-09": -0.27, "2021-12": -0.22, "2022-03": -0.22, "2022-06": -0.28, "2022-09": -0.28, "2022-12": -0.14, "2023-03": -0.15, "2023-06": -0.19, "2023-09": -0.16, "2023-12": -0.12, "2024-03": -0.09, "2024-06": -0.04, "2024-09": -0.16, "2024-12": 0.0139, "2025-03": -0.17, "2025-06": -0.27, "2025-09": -0.24, "2025-12": 0.0132, "2026-03": 0,
EPS CAGR: 119.48%
EPS Trend: 47.5%
Last SUE: 1.98
Qual. Beats: 1
Revenue Revenue of EOLS over the last years for every Quarter: 2021-03: 12.241, 2021-06: 26.098, 2021-09: 26.677, 2021-12: 34.657, 2022-03: 33.908, 2022-06: 37.163, 2022-09: 33.899, 2022-12: 43.646, 2023-03: 41.721, 2023-06: 49.346, 2023-09: 50.019, 2023-12: 60.999, 2024-03: 59.333, 2024-06: 66.909, 2024-09: 61.085, 2024-12: 78.947, 2025-03: 68.522, 2025-06: 69.387, 2025-09: 68.967, 2025-12: 90.3, 2026-03: null,
Rev. CAGR: 29.85%
Rev. Trend: 95.0%
Last SUE: 0.15
Qual. Beats: 0
Risks
Technicals: choppy
Description: EOLS Evolus March 03, 2026

Evolus, Inc. (EOLS) is a performance beauty company focused on the self-pay aesthetic neurotoxin and dermal filler markets. Headquartered in Newport Beach, California, the company commercializes Jeuveau, a specialized botulinum toxin type A formulation, and Evolysse, a line of hyaluronic acid gels. Unlike traditional pharmaceutical firms that rely on insurance reimbursement, Evolus operates within the cash-pay sector, where consumer discretionary spending drives demand.

The medical aesthetics industry is characterized by high barriers to entry due to stringent regulatory requirements for injectable products. Evolus utilizes a digital-first marketing strategy to target millennial and Generation Z consumers, a demographic increasingly seeking preventative aesthetic treatments. Investors may find it useful to examine ValueRay for deeper insights into the companys valuation metrics.

Headlines to Watch Out For
  • Jeuveau sales growth drives revenue expansion
  • European market penetration expands addressable consumer base
  • Regulatory approvals for new products unlock future revenue
  • Competition in neurotoxin market impacts pricing power
Piotroski VR‑10 (Strict, 0-10) 3.0
Net Income: -51.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.21 > 0.02 and ΔFCF/TA -11.64 > 1.0
NWC/Revenue: 22.75% < 20% (prev 33.19%; Δ -10.44% < -1%)
CFO/TA -0.19 > 3% & CFO -42.3m > Net Income -51.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.90 > 1.5 & < 3
Outstanding Shares: last quarter (64.5m) vs 12m ago 1.74% < -2%
Gross Margin: 64.86% > 18% (prev 0.68%; Δ 6.42k% > 0.5%)
Asset Turnover: 129.6% > 50% (prev 114.5%; Δ 15.16% > 0%)
Interest Coverage Ratio: -1.83 > 6 (EBITDA TTM -27.6m / Interest Expense TTM 19.7m)
Altman Z'' -11.42
A: 0.30 (Total Current Assets 142.9m - Total Current Liabilities 75.3m) / Total Assets 225.9m
B: -2.93 (Retained Earnings -661.0m / Total Assets 225.9m)
C: -0.16 (EBIT TTM -36.1m / Avg Total Assets 229.2m)
D: -2.66 (Book Value of Equity -661.2m / Total Liabilities 249.0m)
Altman-Z'' Score: -11.42 = D
Beneish M -2.91
DSRI: 1.03 (Receivables 54.7m/47.7m, Revenue 297.2m/266.3m)
GMI: 1.05 (GM 64.86% / 67.89%)
AQI: 1.02 (AQ_t 0.31 / AQ_t-1 0.30)
SGI: 1.12 (Revenue 297.2m / 266.3m)
TATA: -0.04 (NI -51.6m - CFO -42.3m) / TA 225.9m)
Beneish M-Score: -2.91 (Cap -4..+1) = A
What is the price of EOLS shares? As of March 31, 2026, the stock is trading at USD 3.94 with a total of 820,163 shares traded.
Over the past week, the price has changed by -15.81%, over one month by -8.37%, over three months by -40.93% and over the past year by -67.25%.
Is EOLS a buy, sell or hold? Evolus has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy EOLS.
  • StrongBuy: 4
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the EOLS price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 14.7 272.3%
Analysts Target Price 14.7 272.3%
EOLS Fundamental Data Overview March 27, 2026
P/E Forward = 30.9598
P/S = 0.9567
P/B = 53.7058
Revenue TTM = 297.2m USD
EBIT TTM = -36.1m USD
EBITDA TTM = -27.6m USD
Long Term Debt = 146.1m USD (from longTermDebt, last quarter)
Short Term Debt = 2.53m USD (from shortTermDebt, last quarter)
Debt = 155.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 101.2m USD (from netDebt column, last quarter)
Enterprise Value = 385.5m USD (284.3m + Debt 155.0m - CCE 53.8m)
Interest Coverage Ratio = -1.83 (Ebit TTM -36.1m / Interest Expense TTM 19.7m)
EV/FCF = -7.96x (Enterprise Value 385.5m / FCF TTM -48.5m)
FCF Yield = -12.57% (FCF TTM -48.5m / Enterprise Value 385.5m)
FCF Margin = -16.30% (FCF TTM -48.5m / Revenue TTM 297.2m)
Net Margin = -17.38% (Net Income TTM -51.6m / Revenue TTM 297.2m)
Gross Margin = 64.86% ((Revenue TTM 297.2m - Cost of Revenue TTM 104.4m) / Revenue TTM)
Gross Margin QoQ = 60.85% (prev 66.47%)
Tobins Q-Ratio = 1.71 (Enterprise Value 385.5m / Total Assets 225.9m)
Interest Expense / Debt = 2.57% (Interest Expense 3.98m / Debt 155.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -28.5m (EBIT -36.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.90 (Total Current Assets 142.9m / Total Current Liabilities 75.3m)
 Debt / Equity = -6.71 (negative equity) (Debt 155.0m / totalStockholderEquity, last quarter -23.1m)
 Debt / EBITDA = -3.66 (negative EBITDA) (Net Debt 101.2m / EBITDA -27.6m)
 Debt / FCF = -2.09 (negative FCF - burning cash) (Net Debt 101.2m / FCF TTM -48.5m)
 Total Stockholder Equity = -19.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -22.53% (Net Income -51.6m / Total Assets 225.9m)
 RoE = 267.8% (negative equity) (Net Income TTM -51.6m / Total Stockholder Equity -19.3m)
 RoCE = -28.43% (EBIT -36.1m / Capital Employed (Equity -19.3m + L.T.Debt 146.1m))
 RoIC = -23.64% (negative operating profit) (NOPAT -28.5m / Invested Capital 120.5m)
 WACC = 6.38% (E(284.3m)/V(439.3m) * Re(8.75%) + D(155.0m)/V(439.3m) * Rd(2.57%) * (1-Tc(0.21)))
Discount Rate = 8.75% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.12%
 [DCF] Fair Price = unknown (Cash Flow -48.5m)
 EPS Correlation: 47.52 | EPS CAGR: 119.5% | SUE: 1.98 | # QB: 1
Revenue Correlation: 94.97 | Revenue CAGR: 29.85% | SUE: 0.15 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.05 | Chg7d=-0.047 | Chg30d=-0.077 | Revisions Net=+0 | Analysts=3
EPS current Year (2026-12-31): EPS=-0.12 | Chg7d=+0.000 | Chg30d=-0.050 | Revisions Net=-2 | Growth EPS=+72.7% | Growth Revenue=+11.1%
EPS next Year (2027-12-31): EPS=0.24 | Chg7d=+0.000 | Chg30d=-0.148 | Revisions Net=-2 | Growth EPS=+300.0% | Growth Revenue=+17.6%
[Analyst] Revisions Ratio: -0.50 (1 Up / 3 Down within 30d for Current Year)
Additional Sources for EOLS Stock Fund Manager Positions: Dataroma · Stockcircle